报价延迟最少15分钟:2025/07/21 06:41 EDT
盘前时段
|
||||
|
18.73 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.07/-3.35
|
|
企业价值
769.18M
|
| 资产负债 |
|
每股账面净值
6.67
|
| 现金流量 |
|
现金流量率
0.09
|
| 损益表 |
|
收益
167.50M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 06:41 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
